Clinical Trial

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Study acronym: CAPTAIN-T2D
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Protocol Amendment History 2 changes
notable Trial sites expanded: 52 -> 60 locations 2026-06-18
notable Trial sites expanded: 47 -> 52 locations 2026-05-13
Trial Details
NCT Number NCT07296484
Lead Sponsor Sparrow Pharmaceuticals
Conditions Type 2 Diabetes, Cortisol Excess
Enrollment 1,500 participants
Start Date 2025-11-29
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-17